FY2018 Earnings Estimate for Boston Scientific Corporation Issued By Wedbush (BSX)

Boston Scientific Corporation (NYSE:BSX) – Equities research analysts at Wedbush decreased their FY2018 EPS estimates for Boston Scientific in a research note issued on Thursday. Wedbush analyst Levy. T now expects that the medical equipment provider will post earnings per share of $1.34 for the year, down from their prior estimate of $1.37. Wedbush also issued estimates for Boston Scientific’s FY2019 earnings at $1.46 EPS and FY2020 earnings at $1.60 EPS.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.31. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The company had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same period in the prior year, the business posted $0.27 EPS. The firm’s revenue was up 5.6% compared to the same quarter last year.

A number of other equities research analysts have also commented on BSX. Oppenheimer reiterated a “hold” rating on shares of Boston Scientific in a report on Wednesday, August 9th. BidaskClub upgraded shares of Boston Scientific from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Royal Bank Of Canada reiterated a “buy” rating and set a $31.00 price target on shares of Boston Scientific in a report on Friday, September 1st. Jefferies Group reiterated a “hold” rating on shares of Boston Scientific in a report on Thursday, September 7th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $32.00 price target on shares of Boston Scientific in a report on Monday, September 25th. One research analyst has rated the stock with a sell rating, four have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Boston Scientific presently has a consensus rating of “Buy” and a consensus target price of $30.61.

Boston Scientific (BSX) traded down $0.13 during trading hours on Friday, reaching $26.15. 16,183,181 shares of the company were exchanged, compared to its average volume of 6,852,641. Boston Scientific has a 52 week low of $20.03 and a 52 week high of $29.93. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. The company has a market cap of $35,910.00, a price-to-earnings ratio of 21.63, a P/E/G ratio of 2.04 and a beta of 0.99.

A number of institutional investors have recently modified their holdings of the business. Comerica Securities Inc. grew its position in shares of Boston Scientific by 0.9% in the 2nd quarter. Comerica Securities Inc. now owns 11,478 shares of the medical equipment provider’s stock worth $318,000 after buying an additional 99 shares during the period. ETRADE Capital Management LLC grew its position in shares of Boston Scientific by 1.7% in the 2nd quarter. ETRADE Capital Management LLC now owns 10,079 shares of the medical equipment provider’s stock worth $279,000 after buying an additional 171 shares during the period. Krilogy Financial LLC grew its position in shares of Boston Scientific by 5.9% in the 2nd quarter. Krilogy Financial LLC now owns 7,680 shares of the medical equipment provider’s stock worth $213,000 after buying an additional 430 shares during the period. Wetherby Asset Management Inc. grew its position in shares of Boston Scientific by 3.9% in the 2nd quarter. Wetherby Asset Management Inc. now owns 13,788 shares of the medical equipment provider’s stock worth $382,000 after buying an additional 523 shares during the period. Finally, Greenwood Capital Associates LLC grew its position in shares of Boston Scientific by 1.1% in the 2nd quarter. Greenwood Capital Associates LLC now owns 53,330 shares of the medical equipment provider’s stock worth $1,478,000 after buying an additional 564 shares during the period. 90.55% of the stock is currently owned by institutional investors and hedge funds.

In other Boston Scientific news, EVP Michael P. Phalen sold 15,500 shares of the business’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $28.72, for a total transaction of $445,160.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Valley Gold Master Fund L. Sun acquired 408,006 shares of Boston Scientific stock in a transaction on Tuesday, November 28th. The shares were bought at an average cost of $0.45 per share, for a total transaction of $183,602.70. Over the last three months, insiders have sold 414,698 shares of company stock worth $12,013,153. Insiders own 0.74% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “FY2018 Earnings Estimate for Boston Scientific Corporation Issued By Wedbush (BSX)” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/01/fy2018-earnings-estimate-for-boston-scientific-corporation-issued-by-wedbush-bsx.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Earnings History and Estimates for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply